Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exscientia Ltd ADR
(NQ:
EXAI
)
5.320
+0.020 (+0.38%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Exscientia Ltd ADR
< Previous
1
2
3
4
Next >
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
Today 12:34 EDT
Merging with a former rival will bolster its capabilities.
Via
The Motley Fool
EXAI Stock Earnings: Exscientia Misses EPS, Misses Revenue for Q2 2024
August 15, 2024
EXAI stock results show that Exscientia missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
August 14, 2024
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion...
Via
Talk Markets
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
August 11, 2024
The leading company pioneering artificial intelligence (AI)-fueled drug discovery could get much bigger.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
August 08, 2024
Exscientia merges with Recursion Pharmaceuticals in an all-stock deal. The new entity, named Recursion, will focus on industrializing drug discovery with advanced AI technologies, boasting $850 million...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Exscientia Earnings Preview
March 20, 2024
Via
Benzinga
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
July 30, 2024
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030.
Via
Talk Markets
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
July 18, 2024
To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under...
Via
Talk Markets
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
July 14, 2024
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,...
Via
Talk Markets
3 Small-Cap Stocks With Explosive 2X Growth Potential
July 08, 2024
Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024.
Via
InvestorPlace
Clinical-Stage BioTech Drug Stocks Declined 13% In June
July 01, 2024
Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read
Via
Talk Markets
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
June 22, 2024
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they...
Via
Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
June 17, 2024
The global
Via
Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
June 10, 2024
The global
Via
Talk Markets
The 7 AI Categories Were Down 4%, On Average, This Week; Up 1% In May
June 01, 2024
The 7 AI categories we track dropped, down 4.3% this week, and are now only up 1.3% for the month of May.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
7 Underappreciated Stocks With 25% Return Potential in 2024
May 30, 2024
Each of these underappreciated stocks is expected to provide 25%+ returns this year, which is reason enough to pay attention.
Via
InvestorPlace
The 3 Best Machine Learning Stocks to Quadruple Your Money by 2035
May 23, 2024
One of the hottest investment trends to jump on at the moment is machine learning stocks to buy. Here are three.
Via
InvestorPlace
EXAI Stock Earnings: Exscientia Beats EPS, Misses Revenue for Q1 2024
May 21, 2024
EXAI stock results show that Exscientia beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In
May 20, 2024
The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process...
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
All 7 Artificial Intelligence (AI) Categories Reversed Direction This Week
May 18, 2024
All 7 of the AI categories we track were up 2.9%, on average, this week.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
May 16, 2024
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
May 13, 2024
Via
Talk Markets
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
May 05, 2024
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD.
Via
Talk Markets
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
April 29, 2024
Via
Benzinga
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
April 15, 2024
The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
April 03, 2024
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly...
Via
Benzinga
Exposures
Glyphosate
Six Of Seven AI Stock Categories Increased This Week
March 23, 2024
All but one of the 7 artificial intelligence stock categories that I analyze weekly increased in value this week. But two categories are still down MTD, suggesting that the surge in the artificial...
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
EXAI Stock Earnings: Exscientia Misses EPS, Misses Revenue for Q4 2023
March 21, 2024
EXAI stock results show that Exscientia missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 21, 2024
Via
Benzinga
Earnings Scheduled For March 21, 2024
March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.